(NASDAQ: BCAB) Bioatla's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.57%.
Bioatla's earnings in 2026 is -$64,707,000.On average, 3 Wall Street analysts forecast BCAB's earnings for 2026 to be -$55,170,495, with the lowest BCAB earnings forecast at -$53,006,947, and the highest BCAB earnings forecast at -$56,793,157. On average, 3 Wall Street analysts forecast BCAB's earnings for 2027 to be -$70,162,478, with the lowest BCAB earnings forecast at -$67,411,008, and the highest BCAB earnings forecast at -$72,226,080.
In 2028, BCAB is forecast to generate -$53,971,137 in earnings, with the lowest earnings forecast at -$51,854,622 and the highest earnings forecast at -$55,558,523.